本期看点1. 三代口服酪氨酸激酶抑制剂zanzalintinib联合免疫检查点抑制剂用于初治晚期透明细胞肾细胞癌患者，在一项早期临床试验中的客观缓解率（ORR）达63%，疾病控制率（DCR）为90%。2. 旨在实现肿瘤穿透的双功能抗体ficerafusp alfa联合免疫检查点抑制剂一线治疗复发/转移性头颈鳞状细胞癌（HNSCC）的早期临床试验结果积极，观察到药物靶向TGF-β通路的有效抑制作用。3. 治疗成年杜氏肌营养不良（DMD）男性患者的口服小分子疗法SAT-3247在一项1b期临床试验中使患者的平均握力从约2 kg增加至约4 kg。Zanzalintinib：公布1b/2期联合治疗试验数据Exelixis公司公布了其1b/2期临床试验STELLAR-002的积极结果，该研究旨在评估zanzalintinib联合免疫检查点抑制剂用于初治晚期透明细胞肾细胞癌患者的治疗效果。Zanzalintinib是一种第三代口服酪氨酸激酶抑制剂，靶向VEGFR、MET、AXL和MER等与肿瘤发展、转移及耐药相关的关键通路。此次公布的结果显示，在zanzalintinib联合纳武利尤单抗治疗组的中位随访时间为20.1个月时，ORR达63%，DCR为90%，中位无进展生存期（PFS）为18.5个月。Ficerafusp alfa（BCA101）：公布1/1b期联合治疗试验数据Bicara Therapeutics公司公布了其候选双功能抗体ficerafusp alfa联合帕博利珠单抗一线治疗复发/转移性头颈鳞状细胞癌患者的1/1b期临床试验的新中期数据。Ficerafusp alfa是一种潜在“first-in-class”的双功能抗体，包括一个靶向EGFR的单克隆抗体和一个能够结合人类转化生长因子β（TGF-β）的结构域。通过这种靶向机制，ficerafusp alfa旨在逆转由TGF-β信号传导驱动的纤维化和免疫排除型肿瘤微环境，从而实现肿瘤穿透，促使深度且持久的治疗应答。截至2024年12月16日的数据，在PD-L1综合阳性评分（CPS）≥1、HPV阴性且疗效可评估的28例患者中，ORR达到了64%，完全缓解（CR）率为21%，中位PFS为9.8个月，中位总生存期（OS）已超过20个月。来自成对肿瘤活检的数据表明，治疗后磷酸化SMAD2表达显著下调，支持该药物靶向TGF-β通路的有效抑制作用。此外，安全性数据显示其副作用情况符合预期，并未发现新的安全问题。SAT-3247：公布1b期临床试验数据Satellos Bioscience公司公布了一项针对成年DMD男性患者的1b期临床试验的积极数据。该研究中使用的SAT-3247是一种口服小分子药物，正在开发作为一种新型治疗方法，用于在DMD和其他退行性或损伤情况下丢失骨骼肌的再生。该研究治疗了5名20至27岁的成年男性DMD患者。此次公布的结果显示，SAT-3247具有良好的安全性和耐受性。在同时使用类固醇的DMD患者中，其药代动力学（PK）表现与预期一致。观察到患者有握力显著改善的趋势，平均握力从约2 kg增加至约4 kg。研究结束后，受试者可选择进入11个月的长期随访。基于当前结果，Satellos计划推进该药物进入安慰剂对照的2期临床试验，以进一步评估其疗效与安全性。VLS-1488：公布1/2期临床试验的初步数据Volastra Therapeutics公司公布了其在研口服KIF18A抑制剂VLS-1488的1/2期临床试验的初步结果。VLS-1488是一种新型口服小分子KIF18A抑制剂。KIF18A是一种驱动蛋白，在癌细胞分裂过程中发挥关键作用，并且是染色体不稳定型癌症中的合成致死靶点。2024年10月，该药物被美国FDA授予快速通道资格，用于治疗铂类耐药的高级别浆液性卵巢癌患者。截至2025年1月10日的数据，在剂量递增试验中共纳入52名晚期实体瘤患者。在20名患有晚期高级别浆液性卵巢癌的患者中，大多数为铂类耐药且经过大量前期治疗，平均接受过5线治疗。在疗效可评估的17名患者中，有7人出现了肿瘤缩小，其中包括3例根据RECIST标准确认的部分缓解（PR），另有5名患者仍在继续接受治疗。安全性方面，未发现剂量限制性毒性，仅出现少数3级治疗相关不良事件（TRAE），无高于3级的严重TRAE。RLS-1496：1期临床试验完成首例患者给药Rubedo Life Sciences公司宣布其候选药物RLS-1496在一项针对轻度至中度和稳定型斑块状银屑病患者的1期临床试验中完成了首例患者给药。RLS-1496是一种潜在“first-in-class”的谷胱甘肽过氧化物酶（GPX4）调节剂，专门靶向导致慢性退行性疾病和衰老相关病症的病理衰老“僵尸”细胞。GPX4是一种关键抗氧化酶，保护细胞免受自由基损伤，而GPX4缺乏则与特定类型的细胞死亡（如铁死亡）有关。通过选择性地促进这些敏感细胞的死亡，RLS-1496旨在清除致病细胞，同时支持健康细胞正常功能。新闻稿指出，RLS-1496是首个进入人体临床试验的GPX4调节剂。根据该研究的结果，未来可能将试验扩展至其他炎症性皮肤病和自身免疫疾病，包括但不限于特应性皮炎、白癜风、玫瑰痤疮、斑秃和硬皮病。JUV-161：启动首次人体试验Juvena Therapeutics公司宣布启动其候选药物JUV-161的首次人体临床试验。JUV-161是一种潜在“first-in-class”的融合蛋白，通过促肌生成、调节胰岛素抵抗以及抗炎特性来增强肌肉再生。JUV-161被称为潜在的“肌肉胰岛素”，在多个临床前疾病模型中表现出独特的能力，包括恢复肌纤维形成、对抗肌肉萎缩、增强肌肉力量和耐力，并改善肌肉代谢，这些模型涵盖了从肌营养不良症到因衰老、肥胖、糖尿病和炎症引起的肌肉减少症等疾病。这种长效的研究性生物制品通过激活并恢复AKT信号通路发挥作用，该通路调控细胞存活、生长和代谢，在肌肉萎缩性疾病及自然衰老过程中常常出现失调。JUV-161由Juvena自主研发的AI药物发现与开发平台JuvNET识别确定，其主要作用机制来源于一种经过工程改造的人类类胰岛素生长因子2（IGF2）蛋白，适用于皮下注射。参考资料（可上下滑动查看）[1] Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting. Retrieved May 23, 2025, from https://www.globenewswire.com/news-release/2025/05/18/3083534/0/en/Intellia-Announces-Positive-Two-Year-Follow-Up-Data-from-Ongoing-Phase-1-Study-of-Nexiguran-Ziclumeran-nex-z-in-Patients-with-Hereditary-Transthyretin-ATTR-Amyloidosis-with-Polyneu.html[2] Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025. Retrieved May 23, 2025, from https://www.globenewswire.com/news-release/2025/05/17/3083517/0/en/Tectonic-Therapeutic-Presents-Complete-Results-for-Positive-Phase-1b-Clinical-Trial-of-TX45-in-Patients-with-Group-2-Pulmonary-Hypertension-in-HFpEF-in-Late-Breaking-Presentation-a.html[3] Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia. Retrieved May 23, 2025, from https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-positive-topline-data-from-the-phase-1b2a-disarm-study-of-intravenously-administered-ap-sa02-in-complicated-staphylococcus-aureus-bacteremia-302458664.html[4] Cytora Reports Phase 1 Data of Stem Cell Treatment for Multiple System Atrophy. Retrieved May 23, 2025, from https://www.prnewswire.com/news-releases/cytora-reports-phase-1-data-of-stem-cell-treatment-for-multiple-system-atrophy-302458811.html[5] Atsena Therapeutics Announces Positive Clinical Data from Part A of Phase I/II Trial Evaluating ATSN-201 Gene Therapy to Treat X-linked Retinoschisis (XLRS). Retrieved May 23, 2025, from https://www.globenewswire.com/news-release/2025/05/19/3083910/0/en/Atsena-Therapeutics-Announces-Positive-Clinical-Data-from-Part-A-of-Phase-I-II-Trial-Evaluating-ATSN-201-Gene-Therapy-to-Treat-X-linked-Retinoschisis-XLRS.html[6] AskBio Presents Complete Results of Phase 1 Trial of AB-1002 Gene Therapy in Participants with Congestive Heart Failure at European Society of Cardiology Heart Failure Meeting. Retrieved May 23, 2025, from https://www.globenewswire.com/news-release/2025/05/19/3083984/0/en/AskBio-Presents-Complete-Results-of-Phase-1-Trial-of-AB-1002-Gene-Therapy-in-Participants-with-Congestive-Heart-Failure-at-European-Society-of-Cardiology-Heart-Failure-Meeting.html[7] CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma. Retrieved May 23, 2025, from https://ir.cytomx.com/news-releases/news-release-details/cytomx-therapeutics-announces-first-patient-dosed-combination#:~:text=SOUTH%20SAN%20FRANCISCO%2C%20Calif.%2C%20May%2019%2C%202025%20%28GLOBE,initial%20clinical%20activity%20in%20patients%20with%20metastatic%20melanoma.[8] Juvena Therapeutics Announces Initiation of First-in-Human Clinical Trial of JUV-161. Retrieved May 23, 2025, from https://www.globenewswire.com/news-release/2025/05/19/3083992/0/en/Juvena-Therapeutics-Announces-Initiation-of-First-in-Human-Clinical-Trial-of-JUV-161.html[9] Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease. Retrieved May 23, 2025, from https://investors.primemedicine.com/news-releases/news-release-details/prime-medicine-announces-breakthrough-clinical-data-showing[10] GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals. Retrieved May 23, 2025, from https://www.globenewswire.com/news-release/2025/05/19/3084040/0/en/index.html[11] Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors. Retrieved May 23, 2025, from https://ir.tangotx.com/news-releases/news-release-details/tango-therapeutics-announces-first-patient-dosed-tng456-phase-12#:~:text=BOSTON%2C%20May%2021%2C%202025%20%28GLOBE%20NEWSWIRE%29%20--%20Tango,solid%20tumors%2C%20with%20a%20focus%20on%20glioblastoma%20%28GBM%29.[12] PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Announce The First Follicular Lymphoma (FL) Patient Treated with BAFF-R Targeting CAR-T Cells (PMB-CT01) Achieves a Complete Response. Retrieved May 23, 2025, from https://www.prnewswire.com/news-releases/pepromene-bio-inc-and-the-institute-for-follicular-lymphoma-innovation-ifli-announce-the-first-follicular-lymphoma-fl-patient-treated-with-baff-r-targeting-car-t-cells-pmb-ct01-achieves-a-complete-response-302460318.html[13] Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody. Retrieved May 23, 2025, from https://ir.orukatx.com/news-releases/news-release-details/oruka-therapeutics-announces-first-participants-dosed-phase-1-0[14] Philikos announces initiation of clinical Phase 1/2 study with T-Guard® in patients with systemic sclerosis. Retrieved May 23, 2025, from https://www.globenewswire.com/news-release/2025/05/20/3084824/0/en/Philikos-announces-initiation-of-clinical-Phase-1-2-study-with-T-Guard-in-patients-with-systemic-sclerosis.html[15] Bicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual Meeting. Retrieved May 23, 2025, from https://www.globenewswire.com/news-release/2025/05/22/3087151/0/en/Bicara-Therapeutics-Announces-Publication-of-an-Abstract-with-Updated-Interim-Data-from-Phase-1-1b-Trial-of-Ficerafusp-alfa-in-1L-R-M-HNSCC-at-the-2025-ASCO-Annual-Meeting.html[16] Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate. Retrieved May 23, 2025, from https://avenzotx.com/press-releases/avenzo-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-avzo-1418-a-potential-best-in-class-novel-egfr-her3-bispecific-antibody-drug-conjugate/[17] Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy. Retrieved May 23, 2025, from https://ir.satellos.com/news/news-details/2025/Satellos-Announces-Encouraging-Functional-Data-from-the-28-day-Phase-1b-Open-Label-Trial-of-SAT-3247-in-Adults-with-Duchenne-Muscular-Dystrophy/default.aspx[18] Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496, the First GPX4 Modulator Targeting Pathologic Senescent Cells To Enter Phase 1 Clinical Trial. Retrieved May 23, 2025, from https://www.businesswire.com/news/home/20250522955270/en/Rubedo-Life-Sciences-Announces-First-Patient-Dosed-with-Lead-Drug-Candidate-RLS-1496-the-First-GPX4-Modulator-Targeting-Pathologic-Senescent-Cells-To-Enter-Phase-1-Clinical-Trial?utm_campaign=shareaholic&utm_medium=linkedin&utm_source=socialnetwork[19] Ventus Therapeutics to Present Phase 1 Results for VENT-03, a First-in-Class cGAS Inhibitor, at LUPUS 2025. Retrieved May 23, 2025, from https://www.businesswire.com/news/home/20250521929176/en/Ventus-Therapeutics-to-Present-Phase-1-Results-for-VENT-03-a-First-in-Class-cGAS-Inhibitor-at-LUPUS-2025[20] Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-023 (ARTS-023), a Potential Best-in-Class, Novel CDK4 Selective Inhibitor. Retrieved May 23, 2025, from https://www.businesswire.com/news/home/20250521148693/en/Avenzo-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-AVZO-023-ARTS-023-a-Potential-Best-in-Class-Novel-CDK4-Selective-Inhibitor[21] Volastra Announces Initial Data from First-in-Human Phase I/II Trial of Novel KIF18A Inhibitor VLS-1488 to be Presented at 2025 ASCO Annual Meeting. Retrieved May 23, 2025, from https://www.volastratx.com/initial-data-from-first-in-human-phase-i-ii-trial-of-novel-kif18a-inhibitor-vls-1488/[22] Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025. Retrieved May 23, 2025, from https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-encouraging-results-phase-1b2-stellar-002免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新2

临床结果免疫疗法临床2期

2024-10-23

·BioSpace

Rubedo Life Sciences Announces European Expansion Ahead of First Clinical Trial

Phase 1 dermatology study of lead candidate RLS-1496 to initiate in early 2025 in Europe European headquarters and clinical operations established in Milan, Italy CDP Venture Capital expands Rubedo’s recent Series A along with other new investors SUNNYVALE, Calif.--(BUSINESS WIRE)-- #Italy -- Rubedo Life Sciences , a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, today announced the opening of their European headquarters and clinical operations in Milan. This comes ahead of the company’s first-in-human and Phase 1 study for RLS-1496, a first-in-class treatment for inflammatory skin disease, early next year in Europe. This will be the company’s first clinical trial and operations beyond its world headquarters in California, an acknowledgment of the global impact the diseases of aging have in patients’ lives. “As we make the transition to a clinical stage company, we have an exciting opportunity to leverage world class talent and infrastructure on the Continent to translate our groundbreaking research in the field of cellular senescence into first-in-class therapies for patients with medical skin conditions where senescent cells play a role and skin aging,” said Marco Quarta, CEO & Co-Founder of Rubedo Life Sciences. “With the support of top tier EU investors like CDP Venture Capital, we are thrilled to announce this expansion into Europe as we become a truly global company.” “We are excited to become partners and back the expansion of Rubedo Life Sciences in Italy, reflecting two of the country’s core priorities for the future: driving strategic investments in AI and biotech and fostering the return of top talent. This investment reflects our commitment to supporting innovation while also reinforcing Italy’s position as a hub for these high-impact industries,” said Agostino Scornajenchi, CEO and General Manager of CDP Venture Capital. RLS-1496 is a topically administered therapeutic, and the Phase 1 study will include patients with skin conditions to test safety in primary endpoints. Secondary endpoints will include cellular senescence and disease-associated biomarkers. RLS-1496 has been developed as a topical treatment first to achieve a more efficient proof of concept relative to a systemically administered therapy. About Rubedo Life Sciences Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target various types of senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, technology, and life sciences, with expertise in drug development and commercialization from both large pharma and leading biotech companies. The company is headquartered in Sunnyvale, CA, USA. For additional information, visit . Contacts Media Contact press@rubedolife.com

临床1期细胞疗法

2024-04-23

·药明康德

超10亿美元开发肝病潜在“first-in-class”小分子疗法；7500万美元融资助力抗癌疗法进入3期临床...

▎药明康德内容团队编辑今日，勃林格殷格翰（Boehringer Ingelheim）和益普生（Ipsen）公司均达成数额超过10亿美元的研发和许可合作协议，分别布局包括代谢功能相关脂肪性肝炎（MASH）在内的慢性肝病领域和靶向RNA的小分子疗法。致力于开发潜在“first-in-class”和“best-in-class”疗法的两家新锐公司也成功完成早期融资。预防或逆转肝脏疾病，勃林格殷格翰达成超10亿美元合作勃林格殷格翰今天宣布与Ochre Bio达成研发合作，聚焦于发现和开发治疗慢性肝脏疾病的潜在“first-in-class”再生性疗法。Ochre Bio的专有发现平台结合了机器学习和人类大数据，包括先进的成像和DNA组学数据，以及RNA化学和人类类器官模型。促进发现、检测和验证治疗慢性肝病的创新再生性靶点。这一合作旨在开发有潜力增强肝脏自我修复能力的创新疗法，预防或逆转疾病进展。Ochre Bio将获得3500万美元的前期和近期里程碑付款，以及可超过10亿美元的后续开发、监管和商业化里程碑付款。开发靶向RNA的小分子疗法，益普生达成18亿美元合作益普生和Skyhawk Therapeutics公司宣布达成18亿美元的研发合作，开发调节RNA功能的创新小分子药物，用于治疗罕见神经疾病。Skyhawk Therapeutics公司的平台技术让用小分子探索此前不可成药的RNA靶点成为可能，有望扩展疾病靶点范围。根据协议，益普生有权选择合作产生的两款候选疗法的全球开发权益，在候选疗法获得验证后，将全权负责它们的后续开发和商业化。Skyhawk有资格获得高达18亿美元的开发、监管和商业化里程碑付款。开发潜在“first-in-class”疗法，Rubedo Life Sciences完成4000万美元A轮融资Rubedo Life Sciences公司今日宣布完成4000万美元的A轮融资，获得资金将用于开发靶向衰老细胞（senescent cells）的潜在“first-in-class”疗法，治疗年龄相关疾病。该公司的ALEMBIC药物发现平台旨在选择性靶向不同的衰老细胞，设计潜在“first-in-class”小分子疗法。衰老细胞在肺部、皮肤、肿瘤学疾病，以及神经退行性和纤维化疾病中具有关键作用。该公司的主打在研疗法RLS-1496旨在靶向皮肤中的衰老细胞，治疗特应性皮炎和银屑病，这款小分子疗法即将进入1期临床试验。7500万美元推动潜在“best-in-class”疗法进入3期临床SynOx Therapeutics公司宣布完成7500万美元的B轮融资，获得的资金将用于推动其靶向CSF-1受体的潜在“best-in-class”抗体疗法emactuzumab的3期临床试验和后续开发，用于治疗腱鞘巨细胞瘤（TGCT）。在TGCT患者中，CSF-1的过度表达抑制T细胞介导的抗癌免疫反应。Emactuzumab通过抑制CSF-1受体介导的信号通路，促进T细胞浸润和抗癌免疫反应。此前的临床试验数据显示，emactuzumab达到71%的客观缓解率（ORR），可快速缩小肿瘤并且疗效持久，显著改善患者功能性指标。这些研究同时显示emactuzumab具有良好的安全性和耐受性。新闻稿表示，这款新一代抗体疗法具有成为“best-in-class”的TGCT疗法的潜力。▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料：[1] Rubedo pulls in $40M Series A to advance atopic dermatitis candidate targeting aging cells. Retrieved April 22, 2024, from https://endpts.com/rubedo-pulls-in-40m-series-a-to-advance-atopic-dermatitis-candidate-targeting-aging-cells/[2] Boehringer Ingelheim inks chronic liver disease research pact with Ochre Bio. Retrieved April 22, 2024, from https://endpts.com/boehringer-ingelheim-inks-chronic-liver-disease-research-pact-with-ochre-bio/[3] Irish biotech collects $75M in Series B to start Phase 3 rare joint tumor trial. Retrieved April 22, 2024, from https://endpts.com/synox-raises-75m-in-series-b-to-study-rare-joint-tumor-drug-it-licensed-from-roche/[4] Ipsen, Skyhawk Ink Potential $1.8B Deal to Target RNA in Neuro Diseases. Retrieved April 22, 2024, from https://www.biospace.com/article/ipsen-skyhawk-ink-potential-1-8b-deal-to-target-rna-in-neuro-diseases/[5] Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases. Retrieved April 22, 2024, from https://www.ipsen.com/press-releases/ipsen-and-skyhawk-therapeutics-announce-rna-targeting-research-collaboration-in-rare-neurological-diseases/[6] Disease-modifying therapy targets the senescent skin cells that cause persistent chronic inflammation. Retrieved April 22, 2024, from https://longevity.technology/news/rubedo-announces-first-in-class-drug-candidate-for-dermatology/[7] Ochre Bio announces partnership with Boehringer Ingelheim to develop novel regenerative treatments for patients with advanced liver disease. Retrieved April 22, 2024, from https://www.businesswire.com/news/home/20240422784860/en/Ochre-Bio-announces-partnership-with-Boehringer-Ingelheim-to-develop-novel-regenerative-treatments-for-patients-with-advanced-liver-disease免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

引进/卖出临床3期临床2期突破性疗法临床1期

100 项与 RLS-1496 相关的药物交易

登录后查看更多信息